Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Investing Activities (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Cash from Investing Activities data on record, last reported at -$2.6 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 32.7% year-over-year to -$2.6 million; the TTM value through Sep 2025 reached -$24.8 million, down 4.38%, while the annual FY2024 figure was -$27.5 million, 276.85% down from the prior year.
  • Cash from Investing Activities reached -$2.6 million in Q3 2025 per CRVS's latest filing, up from -$20.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $17.5 million in Q3 2023 and bottomed at -$25.6 million in Q1 2022.
  • Average Cash from Investing Activities over 4 years is -$3.6 million, with a median of -$2.6 million recorded in 2025.
  • Peak YoY movement for Cash from Investing Activities: crashed 308.11% in 2024, then surged 60714.29% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at -$3.9 million in 2022, then soared by 40.29% to -$2.3 million in 2023, then tumbled by 162.42% to -$6.1 million in 2024, then surged by 56.96% to -$2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$2.6 million in Q3 2025, -$20.3 million in Q2 2025, and $4.2 million in Q1 2025.